Brian G. Gazzard
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment.
Journal: The lancet. HIV
Published: October 26, 2022
HIV Antivirals Affect Endothelial Activation and Endothelial-Platelet Crosstalk.
Journal: Circulation research
Published: October 01, 2020
The EuroSIDA study: 25 years of scientific achievements.
Journal: HIV medicine
Published: June 11, 2019
Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk.
Journal: British journal of pharmacology
Published: August 13, 2018
Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
Journal: Journal of neurovirology
Published: January 11, 2018
Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy.
Journal: AIDS (London, England)
Published: January 09, 2018
CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
Journal: Journal of neurovirology
Published: September 18, 2017
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.
Journal: Journal of the American Heart Association
Published: May 24, 2017
Low levels of neurocognitive impairment detected in screening HIV-infected men who have sex with men: The MSM Neurocog Study.
Journal: International journal of STD & AIDS
Published: August 12, 2016
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Journal: The Journal of infectious diseases
Published: June 30, 2016
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
Journal: Lancet (London, England)
Published: September 14, 2015
Last Updated: 09/26/2026